DC-XLEAR
Health Professionals Petition CDC for Guidance: Americans Use Nasal Sprays to Combat COVID-19 Pandemic; Doctors Use in Treating Patients
Today, a consortium of 15 doctors, nurses and other public health professionals petitioned the Centers for Disease Control to issue Guidance calling on: Americans to use nasal sprays to combat the COVID-19 pandemic; and doctors to use them in treating COVID-19 patients.
The petition has also been placed on Change.org and the medical professionals are seeking support for it from all Americans: https://www.change.org/cdcguidance
The petition in particular calls on CDC to tell Americans to use nasal sprays as part of a layered defense against COVID-19. “You wash your hands; you should wash your nose, too. You wear a mask and social distance; you should do that and use a nasal spray,” said Dr. Alonzo Jones, one of the petitioners, and an inventor of one of the studied nasal sprays.
“We have more data supporting the use of nasal sprays against COVID-19 than we had supporting the use of masks and social distancing when CDC told Americans to do those things,” Dr. Mark Cannon, another petitioner, said. “Nasal sprays are inexpensive, non-invasive, safe, and you can get them off-the-shelf at your local store. It’s pure commonsense,” Cannon added.
“We have data showing that certain nasal sprays don’t just wash away the virus. Certain sprays actually block, deactivate and/or kill the virus,” said Dr. Gustavo Ferrer, a respiratory illness expert who has conducted research on the use of nasal sprays to combat COVID-19, and is among the petitioners.
As a result, the petition calls specifically for CDC Guidance to focus on the use of nasal sprays that contain Xylitol and grapefruit seed extract. Recent studies have found that these natural components used together are antiviral (they block SARS-CoV-2 adhesion to the nasal membrane) and virucidal (they kill or deactivate the virus). One such spray, Xlear, is currently widely available in the US. Xlear has been used by millions of people worldwide, over twenty-plus years, without any adverse effects reported.
Additionally, a new, small clinical study found Xlear lessens the severity and shortens the duration of COVID-19 illnesses, and reduces the risk of further transmission, which is why the petition calls for guidance to doctors to use it as an adjunct to current treatments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-LOGITECH19.1.2021 03:02:49 CET | Press release
Logitech’s Q3 Sales Grow 85%, Operating Income Triples
SES18.1.2021 17:42:49 CET | Press release
SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada
APTUM-TECHNOLOGIES18.1.2021 15:02:44 CET | Press release
Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation
GA-PDI18.1.2021 13:02:43 CET | Press release
EG Group Selects PDI to Bring Contactless Payments to its North American Sites
ARGO-BLOCKCHAIN18.1.2021 09:48:48 CET | Press release
Argo Blockchain PLC announces £22.4 Million Private Placement with Institutional Investors and Mining Capacity Expansion
REPLY18.1.2021 09:32:47 CET | Press release
Reply Signs an Agreement with AWS to Develop Industry Solutions
L&T-TECHNOLOGY-SERVICES18.1.2021 09:02:44 CET | Press release
L&T Technology Services Rated as Global Pure-Play ER&D Services Leader by Zinnov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom